Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies

Trial Profile

Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs PDR 001 (Primary)
  • Indications Breast cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 12 Jul 2018 to 20 May 2019.
    • 15 May 2017 Planned End Date changed from 12 Aug 2018 to 12 Jul 2018.
    • 15 May 2017 Planned primary completion date changed from 12 Aug 2018 to 13 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top